company background image

Mega Genomics SEHK:6667 Stock Report

Last Price

HK$16.26

Market Cap

HK$3.9b

7D

17.1%

1Y

n/a

Updated

03 Dec, 2022

Data

Company Financials +
6667 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

6667 Stock Overview

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China.

Mega Genomics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mega Genomics
Historical stock prices
Current Share PriceHK$16.26
52 Week HighHK$21.00
52 Week LowHK$10.10
Beta0
1 Month Change41.39%
3 Month Change-6.34%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-9.67%

Recent News & Updates

A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)

Nov 07
A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)

Recent updates

A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)

Nov 07
A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)

Shareholder Returns

6667HK HealthcareHK Market
7D17.1%8.9%3.7%
1Yn/a-55.4%-21.5%

Return vs Industry: Insufficient data to determine how 6667 performed against the Hong Kong Healthcare industry.

Return vs Market: Insufficient data to determine how 6667 performed against the Hong Kong Market.

Price Volatility

Is 6667's price volatile compared to industry and market?
6667 volatility
6667 Average Weekly Movement11.7%
Healthcare Industry Average Movement8.3%
Market Average Movement8.1%
10% most volatile stocks in HK Market14.9%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 6667 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: Insufficient data to determine 6667's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a386n/a

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer’s disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson’s disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults.

Mega Genomics Limited Fundamentals Summary

How do Mega Genomics's earnings and revenue compare to its market cap?
6667 fundamental statistics
Market CapHK$3.89b
Earnings (TTM)HK$68.20m
Revenue (TTM)HK$263.88m

57.0x

P/E Ratio

14.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6667 income statement (TTM)
RevenueCN¥237.97m
Cost of RevenueCN¥71.29m
Gross ProfitCN¥166.68m
Other ExpensesCN¥105.18m
EarningsCN¥61.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.26
Gross Margin70.04%
Net Profit Margin25.84%
Debt/Equity Ratio0%

How did 6667 perform over the long term?

See historical performance and comparison